PURPOSE: Several strategies have been proposed for the prevention of vancomycin-induced nephrotoxicity. Here, we review available evidence supporting the respective strategies. METHOD: Data were collected by searching the Scopus, PubMed, and Medline databases and the Cochrane database of systematic reviews. The key words used as search terms were "vancomycin," "nephrotoxicity", "renal failure," "renal damage," "nephroprotective," "renoprotective", and "prevention." Prospective or retrospective observational animal studies that evaluated the effects of a modality for the prevention of vancomycin-induced nephrotoxicity was included. RESULTS AND CONCLUSION: Animal studies show beneficial effects of various antioxidants, such as erdosteine, vitamin E, vitamin C, N-acetylcysteine, caffeic acid phenethyl ester, and erythropoietin, in the prevention of vancomycin-induced nephrotoxicity. However, before these agents can be used in clinical practice, their potential benefits must be confirmed in future randomized controlled human studies.
PURPOSE: Several strategies have been proposed for the prevention of vancomycin-induced nephrotoxicity. Here, we review available evidence supporting the respective strategies. METHOD: Data were collected by searching the Scopus, PubMed, and Medline databases and the Cochrane database of systematic reviews. The key words used as search terms were "vancomycin," "nephrotoxicity", "renal failure," "renal damage," "nephroprotective," "renoprotective", and "prevention." Prospective or retrospective observational animal studies that evaluated the effects of a modality for the prevention of vancomycin-induced nephrotoxicity was included. RESULTS AND CONCLUSION: Animal studies show beneficial effects of various antioxidants, such as erdosteine, vitamin E, vitamin C, N-acetylcysteine, caffeic acid phenethyl ester, and erythropoietin, in the prevention of vancomycin-induced nephrotoxicity. However, before these agents can be used in clinical practice, their potential benefits must be confirmed in future randomized controlled human studies.
Authors: Mark H Wilcox; Kenneth J Tack; Emilio Bouza; Daniel L Herr; Bernhard R Ruf; M Marian Ijzerman; Rodney V Croos-Dabrera; Mark J Kunkel; Charles Knirsch Journal: Clin Infect Dis Date: 2009-01-15 Impact factor: 9.079
Authors: L S Elting; E B Rubenstein; D Kurtin; K V Rolston; J Fangtang; C G Martin; I I Raad; E E Whimbey; E Manzullo; G P Bodey Journal: Cancer Date: 1998-12-15 Impact factor: 6.860
Authors: Paul R Ingram; David C Lye; Paul A Tambyah; Wei P Goh; Vincent H Tam; Dale A Fisher Journal: J Antimicrob Chemother Date: 2008-03-10 Impact factor: 5.790
Authors: Rocío Álvarez; Luis E López Cortés; José Molina; José M Cisneros; Jerónimo Pachón Journal: Antimicrob Agents Chemother Date: 2016-04-22 Impact factor: 5.191
Authors: G Ralph Corey; Jeffery Loutit; Greg Moeck; Matthew Wikler; Michael N Dudley; William O'Riordan Journal: Antimicrob Agents Chemother Date: 2018-03-27 Impact factor: 5.191
Authors: Stephen W Davies; Jimmy T Efird; Christopher A Guidry; Zachary C Dietch; Rhett N Willis; Puja M Shah; Sara A Hennessy; Robert G Sawyer Journal: Surg Infect (Larchmt) Date: 2015-09-01 Impact factor: 2.150
Authors: Gwendolyn M Pais; Jiajun Liu; Sanja Zepcan; Sean N Avedissian; Nathaniel J Rhodes; Kevin J Downes; Ganesh S Moorthy; Marc H Scheetz Journal: Pharmacotherapy Date: 2020-05-04 Impact factor: 4.705